查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1406709

焦虑药物市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按产品、适应症、地区和竞争细分

Anxiety Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, Indication, By Region, and By Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年全球焦虑药物市场价值为 115.7 亿美元，预计在预测期内将出现令人印象深刻的成长，到 2028 年CAGR为 2.83%。全球焦虑药物市场是指致力于开发、製造、以及分发旨在治疗焦虑症的药物。焦虑症是一组以过度担心、恐惧和紧张为特征的心理健康状况，会严重影响一个人的日常生活和幸福感。

主要市场驱动因素

焦虑症盛行率上升

市场概况
预测期 2024-2028
2022 年市场规模 115.7亿美元
2028 年市场规模 136.3亿美元
2023-2028 年CAGR 2.83%
成长最快的细分市场 亚太地区
最大的市场 北美洲

焦虑症已成为一种普遍存在的全球健康问题，影响着所有年龄、背景和人口特征的个人。随着焦虑症对社会带来的负担不断增加，对有效治疗的需求也越来越大。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球焦虑药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 副产品（抗忧郁药物、疗法和设备、其他）
    • 依适应症（强迫症、重度忧郁症、恐惧症、其他）
    • 按地区
    • 按公司划分 (2022)
  • 产品市场地图
    • 按产品分类
    • 按指示
    • 按地区

第 6 章：北美焦虑药物市场前景

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 副产品（抗忧郁药物、疗法和设备、其他）
    • 依适应症（强迫症、重度忧郁症、恐惧症、其他）
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲焦虑药物市场前景

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 副产品（抗忧郁药物、疗法和设备、其他）
    • 依适应症（强迫症、重度忧郁症、恐惧症、其他）
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙

第 8 章：亚太地区焦虑药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 副产品（抗忧郁药物、疗法和设备、其他）
    • 依适应症（强迫症、重度忧郁症、恐惧症、其他）
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国

第 9 章：南美洲焦虑药物市场前景

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 副产品（抗忧郁药物、疗法和设备、其他）
    • 依适应症（强迫症、重度忧郁症、恐惧症、其他）
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲焦虑药物市场前景

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 副产品（抗忧郁药物、疗法和设备、其他）
    • 依适应症（强迫症、重度忧郁症、恐惧症、其他）
    • 按国家/地区
  • MEA：国家分析
    • 南非 焦虑药
    • 沙乌地阿拉伯 焦虑药
    • 阿联酋焦虑药
    • 科威特焦虑药

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 13 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • 商业概览
  • 产品供应
  • 最近的发展
  • 财务（据报导）
  • 主要人员
  • SWOT分析
    • AbbVie Inc
    • Bristol-Myers Squibb Co
    • Eli Lilly & Co
    • GSK PLC
    • H Lundbeck A/S
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Pfizer Inc
    • Sanofi SA
    • AstraZeneca PLC

第 15 章：策略建议

第 16 章：关于我们与免责声明

简介目录
Product Code: 19547

Global Anxiety Drugs Market has valued at USD 11.57 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 2.83% through 2028. The global anxiety drugs market refers to the pharmaceutical industry segment dedicated to the development, manufacturing, and distribution of medications aimed at treating anxiety disorders. Anxiety disorders are a group of mental health conditions characterized by excessive worry, fear, and nervousness, which can significantly impact a person's daily life and well-being.

Key Market Drivers

Rising Prevalence of Anxiety Disorders

Market Overview
Forecast Period2024-2028
Market Size 2022USD 11.57 Billion
Market Size 2028USD 13.63 Billion
CAGR 2023-20282.83%
Fastest Growing SegmentAsia Pacific
Largest MarketNorth America

Anxiety disorders have emerged as a pervasive global health concern, affecting individuals of all ages, backgrounds, and demographics. With the burden of anxiety disorders on society increasing, there is a growing demand for effective treatments.

The prevalence of anxiety disorders has reached alarming levels in recent years. According to the World Health Organization (WHO), approximately 3.6% of the global population suffers from anxiety disorders. This statistic translates to hundreds of millions of individuals grappling with conditions such as generalized anxiety disorder, social anxiety disorder, panic disorder, and specific phobias.

A crucial factor contributing to the apparent rise in anxiety disorder prevalence is improved recognition and diagnosis. As mental health awareness campaigns gain momentum and healthcare professionals become better equipped to identify anxiety disorders, more cases are being accurately diagnosed. This leads to an increased demand for appropriate treatments, including anxiety drugs.

Modern lifestyles are marked by high levels of stress and pressure, which can be significant triggers for anxiety disorders. Factors such as demanding work environments, financial stress, and social pressures contribute to the onset or exacerbation of anxiety disorders. As these stressors persist, individuals seek relief through medication, thereby boosting the demand for anxiety drugs.

The global COVID-19 pandemic, which emerged in 2019, has had a profound impact on mental health worldwide. Lockdowns, social isolation, economic uncertainties, and the fear of infection have contributed to a surge in anxiety disorders. Many people who had not previously experienced anxiety found themselves in need of treatment, driving the demand for anxiety drugs during and after the pandemic.

Certain population groups are more vulnerable to anxiety disorders, including veterans, survivors of trauma, and individuals with chronic medical conditions. As the prevalence of these conditions rises, so does the demand for anxiety drugs tailored to address the unique needs of these populations.

Changing societal attitudes toward mental health have led more individuals to seek treatment for their anxiety disorders. People are increasingly recognizing that mental health is as important as physical health, reducing the stigma surrounding mental health conditions and encouraging individuals to seek professional help, including medication.

Increasing Awareness and Mental Health Advocacy

Mental health awareness and advocacy have been steadily gaining momentum worldwide, significantly altering the landscape of healthcare. In this context, the global anxiety drugs market is experiencing transformative growth due to increasing awareness and mental health advocacy.

The stigma surrounding mental health issues has begun to erode as societies across the globe embrace a more empathetic and understanding approach. People are increasingly acknowledging that mental health is an integral part of overall well-being, akin to physical health. This shift in perception encourages individuals to seek help for anxiety disorders, bolstering the demand for anxiety drugs.

Governments, nonprofit organizations, and healthcare providers have launched extensive public awareness campaigns to educate the public about mental health conditions, including anxiety disorders. These campaigns provide information about the signs and symptoms of anxiety and emphasize the importance of early intervention. As individuals become more informed, they are more likely to seek treatment, thus driving the growth of the anxiety drugs market.

Mental health advocacy efforts have been instrumental in reducing the stigma associated with anxiety disorders and other mental health conditions. Celebrities, public figures, and individuals with lived experiences have come forward to share their stories, demonstrating that mental health challenges can affect anyone. This openness fosters an environment where those in need feel more comfortable seeking help, including anxiety drugs.

Mental health advocacy has extended to ensuring that mental health services, including anxiety drugs, are accessible and affordable. Efforts to improve insurance coverage for mental health treatments and reduce the financial burden on patients have made it easier for individuals to obtain the medications they need to manage anxiety disorders.

Mental health advocacy groups often champion increased funding for research into anxiety disorders and the development of novel treatments. Pharmaceutical companies are encouraged to invest in research and innovation, leading to the creation of more effective and safer anxiety drugs. This continuous improvement in treatment options contributes to the growth of the global anxiety drugs market.

Advocacy efforts have promoted the integration of mental health services, including the prescription of anxiety drugs, within primary care settings. This ensures that individuals receive comprehensive healthcare that addresses both physical and mental health needs.

Telehealth and Digital Health Platforms

The digital revolution in healthcare has paved the way for transformative changes in the treatment of mental health conditions, including anxiety disorders. Telehealth and digital health platforms have emerged as powerful tools for expanding access to care and treatment options.

The advent of telehealth and digital health platforms has ushered in a new era of healthcare delivery. These technologies leverage the power of the internet, smartphones, and other digital devices to provide convenient and accessible healthcare services. In the context of mental health, this has significant implications for individuals struggling with anxiety disorders.

Telehealth and digital health platforms break down geographical barriers, allowing individuals to connect with mental health professionals from the comfort of their homes. This expanded access to care is particularly valuable for individuals who may live in remote areas or have limited mobility, making it easier for them to seek treatment, including anxiety drugs.

Telehealth and digital platforms also help mitigate the stigma associated with mental health issues. For some individuals, the fear of judgment or shame may deter them from seeking in-person care. However, the relative anonymity and privacy of virtual consultations can encourage more people to reach out for help and receive prescriptions for anxiety drugs when necessary.

Digital health platforms offer unparalleled convenience. Patients can schedule appointments at times that suit their schedules and receive timely care, often with shorter waiting times compared to traditional in-person visits. This ease of access is crucial for individuals in acute distress or experiencing severe anxiety symptoms.

Telehealth platforms are equipped to manage medication prescriptions effectively. Mental health professionals can assess a patient's needs remotely and prescribe anxiety drugs as part of a comprehensive treatment plan. This feature ensures that patients receive the right medications, reducing the risk of treatment gaps or discontinuation.

Digital health platforms often include features to remind patients to take their medications on time. This enhances medication adherence, a critical factor in the successful management of anxiety disorders. Patients are more likely to follow their treatment regimens when they receive digital reminders and have access to support from healthcare providers via telehealth.

Digital health platforms can collect and analyze patient data, providing valuable insights into treatment effectiveness. This data-driven approach allows healthcare providers to personalize anxiety drug regimens, tailoring treatments to the specific needs of individual patients for better outcomes.

Stressful Lifestyles and the Pandemic Effect

In a world characterized by rapidly changing lifestyles and unprecedented challenges like the COVID-19 pandemic, mental health concerns, especially anxiety disorders, have become increasingly prevalent.

Modern life is often synonymous with a fast-paced, demanding existence. Individuals grapple with a multitude of stressors, including job pressures, financial worries, and the challenges of maintaining work-life balance. These stressors can be significant triggers for anxiety disorders, driving the demand for effective anxiety drugs.

The relentless demands of the modern workplace contribute significantly to elevated stress levels. Long working hours, tight deadlines, and the constant need to adapt to technological changes can lead to heightened anxiety. As employees experience mounting stress, they may seek anxiety drugs to manage their symptoms.

Economic downturns, recessions, and financial instability can take a toll on individuals' mental well-being. Fear of job loss, financial insecurity, and the pressures of making ends meet during challenging economic times can exacerbate anxiety disorders, increasing the need for anxiety drugs.

Social pressures and the feeling of isolation in an increasingly digital and connected world can contribute to anxiety disorders. Social anxiety and loneliness are prevalent issues that may require pharmaceutical interventions, further driving the growth of the anxiety drugs market.

The COVID-19 pandemic, which emerged in 2019, has had an unprecedented impact on mental health worldwide. Lockdowns, social isolation, health concerns, and the disruption of normal life have caused a surge in anxiety disorders. Many individuals who had not previously experienced anxiety found themselves in need of treatment, boosting the demand for anxiety drugs during and after the pandemic.

The pandemic introduced a level of fear and uncertainty that few had experienced before. Fear of contracting the virus, concerns about the health of loved ones, and uncertainty about the future became constant companions for many. These emotions can lead to heightened anxiety, prompting individuals to seek relief through anxiety medications.

Key Market Challenges

Safety and Side Effects

Anxiety drugs, like all medications, can come with side effects. Balancing the effectiveness of these drugs with the potential for adverse reactions is a continual challenge. Pharmaceutical companies must invest in research and development to minimize side effects while maintaining therapeutic benefits.

Stigma Surrounding Mental Health

Despite increased awareness, stigma surrounding mental health issues persists in many societies. The fear of judgment or discrimination may deter some individuals from seeking help for anxiety disorders, thereby limiting the market's potential growth. Overcoming this stigma remains a significant challenge.

Treatment Resistance

Some individuals with anxiety disorders do not respond well to available treatments, including anxiety drugs. Developing more effective drugs for treatment-resistant cases poses a challenge for pharmaceutical companies and researchers.

Key Market Trends

Biotechnology and Targeted Therapies

Biotechnology is playing a pivotal role in the development of targeted therapies for anxiety disorders. Researchers are exploring the use of monoclonal antibodies and other biologics to modulate specific neurotransmitters and receptors implicated in anxiety. These therapies offer the potential for highly precise treatments.

Novel Drug Classes

Pharmaceutical companies are actively researching and developing novel drug classes for anxiety treatment. These include medications targeting previously unexplored neurotransmitter systems or utilizing innovative delivery methods. The pursuit of more effective and safer anxiety drugs is ongoing.

Digital Therapeutics

Digital therapeutics, in the form of smartphone apps and online platforms, are emerging as complementary tools for anxiety management. These digital solutions offer cognitive-behavioral therapy (CBT) and mindfulness-based interventions, which can be used alongside anxiety drugs or as standalone treatments. They provide convenience and accessibility, especially for those uncomfortable with traditional therapy.

Segmental Insights

Product Insights

Based on the category of Product, Antidepressant drugs are poised to dominate the global anxiety drugs market in 2022 for several compelling reasons. First and foremost, the prevalence of anxiety disorders is on the rise worldwide, driven by factors such as increased stress levels, changing lifestyles, and the lingering effects of the COVID-19 pandemic. Antidepressants, which often have dual indications for treating both depression and anxiety, are well-positioned to address this growing demand for anxiety management. Additionally, pharmaceutical companies are continually investing in research and development to introduce innovative antidepressant medications with enhanced efficacy and fewer side effects, further bolstering their dominance in the market. Moreover, the established market presence of well-known antidepressant brands, along with extensive marketing and promotional activities, contributes to their widespread recognition and acceptance among healthcare professionals and patients alike. As a result, it is highly likely that antidepressant drugs will continue to hold a prominent share in the global anxiety drugs market in the foreseeable future.

Indication Insights

Based on Indication, it is anticipated that the Major Depressive Disorder (MDD) segment will maintain a substantial market share throughout the projected period. Major depressive disorder stands as the primary contributor to the global burden of mental health conditions. The COVID-19 pandemic brought about a multitude of uncertainties impacting mental health, including factors such as virus transmission, lockdowns, public transport restrictions, school and business closures, and reduced social interaction. These factors escalated the potential risk of MDD, thereby amplifying the global burden of mental health. The prevalence of major depressive disorder has been on the rise, and the introduction of new products by key industry players is expected to fuel market growth in the forecast period. For example, an article published in Elsevier Journal in October 2021 reported a 26.7% increase in the prevalence of major depressive disorder in 2021, with a total prevalence of 3152.9 cases per 100,000 population in 2020. Such high prevalence of major depressive disorder worldwide is projected to drive demand for effective treatments, thus contributing to the segment's growth in the foreseeable future.

Furthermore, the growth of this studied segment is also expected to be bolstered by the continued launch of new products by major market players. For instance, in December 2021, Dr. Reddy introduced venlafaxine ER Tablets in the U.S. market, a therapeutic equivalent to Osmotica Pharmaceutical U.S. LLC's Venlafaxine Extended-Release Tablets in 150mg and 225mg strengths. These tablets, categorized as selective serotonin and norepinephrine reuptake inhibitors (SNRIs), are indicated for the treatment of major depressive disorder (MDD) and social anxiety disorder (SAD). Additionally, in October 2021, Biogen Inc. and Sage Therapeutics Inc. sought FDA approval for zuranolone as a treatment for MDD. The initial submission package for MDD will incorporate data from ongoing pharmacology and clinical studies, as well as data from the LANDSCAPE and NEST clinical trial programs, encompassing several studies evaluating the effectiveness of zuranolone in various dosing regimens, treatment approaches, and clinical outcomes.

Consequently, the factors mentioned above, including the increasing prevalence of major depressive disorders and ongoing product innovations, are poised to drive growth within this segment.

Regional Insights

In the forthcoming period, it is anticipated that North America will maintain a substantial presence in the market. This projection is underpinned by several key factors, including the escalating incidence of anxiety and depression disorders within the North American populace, the prominent presence of major industry players, and a robust clinical pipeline, all of which are poised to stimulate market expansion.

For example, data published by the Anxiety and Depression Association of America in 2022 reveals that anxiety disorders afflict 6.8 million adults in the United States and impact more than 31.9% of adolescents aged 13 to 18 in 2021. Similarly, statistics from the Canadian Mental Health Association, released in July 2021, indicate that major depressive disorder affected approximately 5.4% of the Canadian population, while anxiety disorders affected 4.6% of the population in 2021. Consequently, the escalating prevalence of anxiety and depression within North American countries is expected to be a driving force behind market growth during the forecast period.

Furthermore, the upsurge in product approvals within this region is also anticipated to propel market expansion. For instance, in August 2022, the US FDA granted approval to Axsome Therapeutics' product, Auvelity, for the treatment of major depressive disorder in adults. This orally administered product boasts a novel mechanism of action, further reinforcing its potential to drive market growth.

Key Market Players

AbbVie Inc

Bristol-Myers Squibb Co

Eli Lilly & Co

GSK PLC

H Lundbeck A/S

Johnson & Johnson

Merck & Co., Inc.

Pfizer Inc

Sanofi SA

AstraZeneca PLC

Report Scope:

In this report, the Global Anxiety Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anxiety Drugs Market, By Product:

  • Antidepressant Drugs
  • Therapy and Devices
  • Others

Anxiety Drugs Market, By Indication:

  • Obsessive-Compulsive Disorder
  • Major Depressive Disorder
  • Phobia
  • Others

Anxiety Drugs Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Anxiety Drugs Market.

Available Customizations:

  • Global Anxiety Drugs market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anxiety Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Antidepressant Drugs, Therapy and Devices, Others)
    • 5.2.2. By Indication (Obsessive-Compulsive Disorder, Major Depressive Disorder, Phobia, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Product Market Map
    • 5.3.1. By Product
    • 5.3.2. By Indication
    • 5.3.3. By Region

6. North America Anxiety Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product (Antidepressant Drugs, Therapy and Devices, Others)
    • 6.2.2. By Indication (Obsessive-Compulsive Disorder, Major Depressive Disorder, Phobia, Others)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Anxiety Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Indication
    • 6.3.2. Canada Anxiety Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Indication
    • 6.3.3. Mexico Anxiety Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Indication

7. Europe Anxiety Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product (Antidepressant Drugs, Therapy and Devices, Others)
    • 7.2.2. By Indication (Obsessive-Compulsive Disorder, Major Depressive Disorder, Phobia, Others)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Anxiety Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Indication
    • 7.3.2. United Kingdom Anxiety Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Indication
    • 7.3.3. France Anxiety Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Indication
    • 7.3.4. Italy Anxiety Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Indication
    • 7.3.5. Spain Anxiety Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Indication

8. Asia-Pacific Anxiety Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product (Antidepressant Drugs, Therapy and Devices, Others)
    • 8.2.2. By Indication (Obsessive-Compulsive Disorder, Major Depressive Disorder, Phobia, Others)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Anxiety Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Indication
    • 8.3.2. Japan Anxiety Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Indication
    • 8.3.3. India Anxiety Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Indication
    • 8.3.4. Australia Anxiety Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Indication
    • 8.3.5. South Korea Anxiety Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Indication

9. South America Anxiety Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product (Antidepressant Drugs, Therapy and Devices, Others)
    • 9.2.2. By Indication (Obsessive-Compulsive Disorder, Major Depressive Disorder, Phobia, Others)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Anxiety Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Indication
    • 9.3.2. Argentina Anxiety Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Indication
    • 9.3.3. Colombia Anxiety Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Indication

10. Middle East and Africa Anxiety Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product (Antidepressant Drugs, Therapy and Devices, Others)
    • 10.2.2. By Indication (Obsessive-Compulsive Disorder, Major Depressive Disorder, Phobia, Others)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Anxiety Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Indication
    • 10.3.2. Saudi Arabia Anxiety Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Indication
    • 10.3.3. UAE Anxiety Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Indication
    • 10.3.4. Kuwait Anxiety Drugs Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Product
        • 10.3.4.2.2. By Indication

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. AbbVie Inc
    • 14.6.2. Bristol-Myers Squibb Co
    • 14.6.3. Eli Lilly & Co
    • 14.6.4. GSK PLC
    • 14.6.5. H Lundbeck A/S
    • 14.6.6. Johnson & Johnson
    • 14.6.7. Merck & Co., Inc.
    • 14.6.8. Pfizer Inc
    • 14.6.9. Sanofi SA
    • 14.6.10. AstraZeneca PLC

15. Strategic Recommendations

16. About Us & Disclaimer